EW
VBIV

Evoke Wealth’s VBI Vaccines, Inc. New Common Stock (Canada) VBIV Stock Holding History

Evoke Wealth’s Portfolio VBIV Stock Details VBIV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-25
Closed -$2K – 1272
2021
Q4 		$2K Hold
25
– – ﹤0.01% 1086
2021
Q3 		$2K Hold
25
– – ﹤0.01% 1040
2021
Q2 		$2K Hold
25
– – ﹤0.01% 1083
2021
Q1 		$2K Hold
25
– – ﹤0.01% 1067
2020
Q4 		$2K Buy
+25
New +$2.13K ﹤0.01% 920

Other funds holding VBIV

PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $44.6B AUM 28.94% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
GAI
General American Investors New York $1.69B AUM 40.94% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return
Rafferty Asset Management
Rafferty Asset Management New York $43.9B AUM 121.74% 1-Year Est. Return

Evoke Wealth's VBIV Position: Q1 2022 in Review

Evoke Wealth sold out of VBI Vaccines, Inc. New Common Stock (Canada) (VBIV) in Q1 2022, closing a stake of 25 shares — an estimated $2K sold.

Evoke Wealth first reported a position in VBIV in Q4 2020 and held it in 5 quarters. The position peaked at $2K in Q4 2021. 131 funds tracked by Wall St. Rank hold VBIV as of Q1 2022.

  • Evoke Wealth reported no remaining VBI Vaccines, Inc. New Common Stock (Canada) position as of Q1 2022 after selling out during the quarter.
  • Evoke Wealth sold 25 VBI Vaccines, Inc. New Common Stock (Canada) shares in Q1 2022, an estimated $2K.
  • Evoke Wealth first reported a position in VBI Vaccines, Inc. New Common Stock (Canada) in Q4 2020 and held it in 5 quarters.
  • Evoke Wealth's VBI Vaccines, Inc. New Common Stock (Canada) position peaked at $2K in Q4 2021.
  • 131 funds tracked by Wall St. Rank held VBI Vaccines, Inc. New Common Stock (Canada) as of Q1 2022.

Based on Evoke Wealth's 13F filing for Q1 2022, filed 10 May 2022.